C. Galéa

发表

Phase-I study of Innacell γδ™, an autologous cell-therapy product highly enriched in γ9δ2 T lymphocytes, in combination with IL-2, in patients with metastatic renal cell carcinoma

M. Rimbert, I. Philip, E. Bompas, 2008, Cancer Immunology, Immunotherapy.

Phase I study of bromohydrin pyrophosphate (BrHPP, IPH 1101), a Vγ9Vδ2 T lymphocyte agonist in patients with solid tumors

M. Rimbert, H. Bruzzoni-Giovanelli, F. Calvo, 2010, Cancer Immunology, Immunotherapy.